Drug and alcohol dependence · 2025
Mortality during and following treatment with extended-release naltrexone based on data from two clinical trials.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Gjersing L, Tanum L, Weimand B, Solli K K
Аннотация
AIMS: To examine mortality during and in the first year following extended-release naltrexone (XR-NTX) treatment in patients with opioid use disorder (OUD).
DESIGN: A prospective registry study.
SETTING: Two clinical trials in Norway.
PARTICIPANTS: A total of 268 XR-NTX patients from two clinical trials conducted from 2013 to 2022.
MEASUREMENTS: Data from the inclusion interviews were cross-linked with data from the Norwegian Cause of Death Registry. Mortality during treatment was estimated for the first 30 days following a XR-NTX injection, while mortality following treatment cessation was examined from day 31 after the final XR-NTX injection until death or censoring. Surviving individuals were censored at 365 days. Crude mortality rates (CMR) and 95 % Confidence Intervals (CI) were calculated per 100 person-years (PY). We used the Kaplan-Meier method to estimate the survival functions and the log-rank test to compare survival distributions across different groups; male (no/yes), age (<30 years, 30-39 years, >39 years), injecting drug use (IDU) (no/yes), lifetime non-fatal overdose (no/yes), and treatment duration for six months (no/yes).
FINDINGS: Overall, there was only one non-drug-related death during treatment. In the year following treatment cessation,12 individuals died; two within the first 30 days. Ten of these deaths were from accidental poisonings. The overall CMR was 4.6 (95 % CI 2.5-7.5) per 100 PY, CONCLUSION: The XR-NTX patients in the two clinical trials appeared to be protected from overdose death while in treatment but faced an elevated mortality risk in the year following treatment cessation.
DESIGN: A prospective registry study.
SETTING: Two clinical trials in Norway.
PARTICIPANTS: A total of 268 XR-NTX patients from two clinical trials conducted from 2013 to 2022.
MEASUREMENTS: Data from the inclusion interviews were cross-linked with data from the Norwegian Cause of Death Registry. Mortality during treatment was estimated for the first 30 days following a XR-NTX injection, while mortality following treatment cessation was examined from day 31 after the final XR-NTX injection until death or censoring. Surviving individuals were censored at 365 days. Crude mortality rates (CMR) and 95 % Confidence Intervals (CI) were calculated per 100 person-years (PY). We used the Kaplan-Meier method to estimate the survival functions and the log-rank test to compare survival distributions across different groups; male (no/yes), age (<30 years, 30-39 years, >39 years), injecting drug use (IDU) (no/yes), lifetime non-fatal overdose (no/yes), and treatment duration for six months (no/yes).
FINDINGS: Overall, there was only one non-drug-related death during treatment. In the year following treatment cessation,12 individuals died; two within the first 30 days. Ten of these deaths were from accidental poisonings. The overall CMR was 4.6 (95 % CI 2.5-7.5) per 100 PY, CONCLUSION: The XR-NTX patients in the two clinical trials appeared to be protected from overdose death while in treatment but faced an elevated mortality risk in the year following treatment cessation.